# A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

> **NCT01631097** · PHASE1 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 44 (estimated)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Tivozanib hydrochloride

## Key facts

- **NCT ID:** NCT01631097
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2014-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01631097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01631097, "A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01631097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*